FLGT Fulgent Genetics, Inc.
Fulgent Genetics, Inc. (FLGT) is expected to report earnings on October 29, 2026, after the market close. The consensus earnings estimate is a loss of $1.00 per share, and the stock has had a Post-Earnings Announcement Drift (PEAD) of +7.1% since its last earnings release on July 30, 2026.
Sign in or subscribe to unlock sentiment, short interest, and technical indicators.
Whisperings™
About Fulgent Genetics, Inc.
Fulgent Genetics’ proprietary technology platform has created a broad, flexible test menu and the ability to continually expand and improve its proprietary genetic reference library while maintaining accessible pricing, high accuracy and competitive turnaround times.
Sector
Healthcare
Industry
Medical Labs & Research